[go: up one dir, main page]

LT3989962T - Kompleksinė terapija acetilleucinu ir miglustatu, skirta lizosominės kaupimo ligos gydymui - Google Patents

Kompleksinė terapija acetilleucinu ir miglustatu, skirta lizosominės kaupimo ligos gydymui

Info

Publication number
LT3989962T
LT3989962T LTEPPCT/IB2020/056096T LTIB2020056096T LT3989962T LT 3989962 T LT3989962 T LT 3989962T LT IB2020056096 T LTIB2020056096 T LT IB2020056096T LT 3989962 T LT3989962 T LT 3989962T
Authority
LT
Lithuania
Prior art keywords
miglustat
leucine
acetyl
treating
combination therapy
Prior art date
Application number
LTEPPCT/IB2020/056096T
Other languages
English (en)
Inventor
Mallory Factor
Michael Strupp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of LT3989962T publication Critical patent/LT3989962T/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
LTEPPCT/IB2020/056096T 2019-06-28 2020-06-26 Kompleksinė terapija acetilleucinu ir miglustatu, skirta lizosominės kaupimo ligos gydymui LT3989962T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962868383P 2019-06-28 2019-06-28
US201962931003P 2019-11-05 2019-11-05
PCT/IB2020/056096 WO2020261230A1 (en) 2019-06-28 2020-06-26 Combination therapy with acetyl-leucine and miglustat

Publications (1)

Publication Number Publication Date
LT3989962T true LT3989962T (lt) 2025-10-10

Family

ID=71452519

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/IB2020/056096T LT3989962T (lt) 2019-06-28 2020-06-26 Kompleksinė terapija acetilleucinu ir miglustatu, skirta lizosominės kaupimo ligos gydymui

Country Status (16)

Country Link
US (1) US20220362189A1 (lt)
EP (2) EP4650003A3 (lt)
DK (1) DK3989962T3 (lt)
ES (1) ES3048174T3 (lt)
FI (1) FI3989962T3 (lt)
HR (1) HRP20251256T1 (lt)
HU (1) HUE073420T2 (lt)
LT (1) LT3989962T (lt)
MA (1) MA56386B1 (lt)
MD (1) MD3989962T2 (lt)
PL (1) PL3989962T3 (lt)
PT (1) PT3989962T (lt)
RS (1) RS67283B1 (lt)
SI (1) SI3989962T1 (lt)
SM (1) SMT202500369T1 (lt)
WO (1) WO2020261230A1 (lt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201709459D0 (en) 2017-06-14 2017-07-26 Intrabio Ltd Treatment for migraine
MA54289A (fr) * 2018-12-06 2021-10-06 Intrabio Ltd Analogues deutérés d'acétyl-leucine
CN118409027B (zh) * 2024-07-02 2024-09-10 成都市食品检验研究院 一种食品中1-脱氧野尻霉素的含量检测方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT201600385T1 (it) 2010-06-25 2017-03-08 Shire Human Genetic Therapies Trasporto di agenti terapeutici all’snc
CA3033557A1 (en) * 2016-08-11 2018-02-15 Intrabio Limited Pharmaceutical compositions and uses directed to lysosomal storage disorders

Also Published As

Publication number Publication date
EP4650003A2 (en) 2025-11-19
EP3989962B1 (en) 2025-08-27
DK3989962T3 (da) 2025-10-13
US20220362189A1 (en) 2022-11-17
FI3989962T3 (fi) 2025-10-08
SI3989962T1 (sl) 2025-11-28
HRP20251256T1 (hr) 2025-12-05
PT3989962T (pt) 2025-10-09
EP3989962A1 (en) 2022-05-04
RS67283B1 (sr) 2025-11-28
MD3989962T2 (ro) 2025-12-31
MA56386B1 (fr) 2025-10-31
EP4650003A3 (en) 2026-01-21
HUE073420T2 (hu) 2026-01-28
ES3048174T3 (en) 2025-12-09
PL3989962T3 (pl) 2025-11-17
MA56386A (fr) 2022-05-04
SMT202500369T1 (it) 2025-11-10
WO2020261230A1 (en) 2020-12-30

Similar Documents

Publication Publication Date Title
SI3989962T1 (sl) Kombinirano zdravljenje z acetil-levcinom in miglustatom za zdravljenje lizosomske bolezni kopičenja
SG11202001445XA (en) Engineered dnase enzymes and use in therapy
GB202018667D0 (en) Photodynamic therapy and diagnosis
HK40127928A (en) Combination therapy with acetyl-leucine and miglustat for treating a lysosomal storage disease
IL288178A (en) Combined gmci and ddri treatment for cancer
GB202103164D0 (en) Therapy
GB202004189D0 (en) Combination therapy
GB202208157D0 (en) Photodynamic therapy and diagnosis
GB202208170D0 (en) Photodynamic therapy and diagnosis
GB202208167D0 (en) Photodynamic therapy and diagnosis
GB202208166D0 (en) Photodynamic therapy and diagnosis
GB202208165D0 (en) Photodynamic therapy and diagnosis
GB202208164D0 (en) Photodynamic therapy and diagnosis
GB202208161D0 (en) Photodynamic therapy and diagnosis
GB202018672D0 (en) Photodynamic therapy and diagnosis
GB202018673D0 (en) Photodynamic therapy and diagnosis
GB202018671D0 (en) Photodynamic therapy and diagnosis
GB202018668D0 (en) Photodynamic therapy and diagnosis
GB202018669D0 (en) Photodynamic therapy and diagnosis
GB202109373D0 (en) Combination therapy
GB202109375D0 (en) Combination therapy
GB202117706D0 (en) Therapy
GB202107713D0 (en) Combination therapy
GB202015916D0 (en) Combination therapy
GB202019218D0 (en) Therapy